XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko Purchases 2,000 Shares of Stock

XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko acquired 2,000 shares of XOMA stock in a transaction on Monday, April 7th. The stock was purchased at an average cost of $24.70 per share, with a total value of $49,400.00. Following the purchase, the executive now directly owns 5,045 shares of the company’s stock, valued at approximately $124,611.50. This trade represents a 65.68 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Bradley Sitko also recently made the following trade(s):

• On Friday, March 21st, Bradley Sitko acquired 4,134 shares of XOMA stock. The stock was purchased at an average cost of $23.89 per share, with a total value of $98,761.26.

XOMA Stock Performance

Shares of XOMA opened at $20.19 on Thursday. The firm has a market cap of $241.86 million, a PE ratio of -5.80 and a beta of 1.00. The stock’s fifty day moving average price is $22.36 and its two-hundred day moving average price is $26.30. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. XOMA Co. has a 1 year low of $18.35 and a 1 year high of $35.00.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $8.70 million during the quarter, compared to analysts’ expectations of $8.75 million. On average, equities research analysts forecast that XOMA Co. will post -1.41 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. StockNews.com cut XOMA from a “hold” rating to a “sell” rating in a research note on Thursday, April 3rd. HC Wainwright reissued a “buy” rating and issued a $104.00 price objective on shares of XOMA in a research note on Friday, March 28th.

Hedge Funds Weigh In On XOMA

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in XOMA by 1,063.8% in the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,585 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the period. New York State Common Retirement Fund raised its stake in XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 800 shares during the last quarter. Wells Fargo & Company MN raised its stake in XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 1,183 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 2,009 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.